Introduction
Cardiac defects are the most common birth defect and affect approximately 0.8% of newborns [1] . In Switzerland, every year approximately 700 children are born with congenital heart disease (CHD). Half of these children have simple defects (e.g., a ventricular septal defect), the other half have moderately complex (e.g., coarctation of the aorta) or complex (e.g., transposition of the great arteries) defects. Many of the simple defects close spontaneously during the first years of life, but eventually 200 to 300 of the infants with CHD will require an intervention. Nowadays, more than 90% of children with repaired CHD survive into adulthood [2] . The majority of them enter adult life with the need for a lifelong specialised follow-up. In the current era, the number of grown-up CHD (GUCH) patients has outgrown the paediatric CHD cohort: two out of three CHD patients are adults [3] . With further reductions in mortality resulting from advances in diagnostic methods, cardiac surgery, catheter interventions and electrophysiology, the prevalence of GUCH patients will continue to increase. It is estimated that currently 2.5 million adults with CHD are living in Europe, of whom 20 000 in Switzerland [4] . The following review article highlights historical milestones in CHD and the resulting challenges GUCH patients have to face during their lifetime.
Historical background
The medical success story of CHD was strongly related to pioneering work in cardiac surgery, and started with a palliation procedure. In 1945, the John Hopkins' surgeon Alfred Blalock performed a shunt operation in a 15-monthold child with cyanotic heart disease and reduced pulmonary blood flow. He sutured the left subclavian artery end-to-side on the left pulmonary artery ( fig. 1) , with the aim to increase pulmonary blood flow without the risk of inducing shunt-related pulmonary hypertension. This procedure, later called the Blalock-Taussig shunt, reduced CHD mortality from 23 to 17% in older cyanotic children [5] . In 1952, palliative procedures were succeeded by intracardiac surgery. James Lewis closed an atrial septal defect in a 5-year-old girl, using a special clamp technique to avoid exsanguination of the beating heart. In 1955, John W. Kirklin at the Mayo Clinic in Rochester reported the successful use of a heart-lung machine and heralded the era of open-heart surgery with use of extracorporeal circula-tion. However, the reported mortality for intracardiac correction of tetralogy of Fallot, the most common cyanotic defect, was 39% with the heart-lung machine, substantially higher than the reported 17% mortality after palliation with a Blalock-Taussig shunt [6] . The policy was adopted to initially palliate complex defects by a shunt or banding procedure with the aim to gain time and let the infants and their cardiovascular structures grow, and thereby delay the repair of the cardiac defect into early childhood (secondary repair). During the 1970s, a new intraoperative strategy was established, consisting of cooling the patient to about 20°C on the heart-lung machine, with subsequent cardiac arrest during the repair operation, followed by rewarming prior to weaning from the bypass. With this strategy, correction of almost all cardiac anomalies was progressively mastered. Further advances in surgical techniques and perioperative care allowed a stepwise abandonment of secondary repair strategies for primary repair, without the need for an initial palliation procedure. Even the most complex lesions, such as a heart with a single ventricle due to hypoplasia of one of the ventricles, can nowadays be approached (fig. 2) [7] . Contemporary mortality in the first year of life for children with non-severe CHD is now 2 to 4%, with an operative mortality of 0 to 2%. For children with severe CHD, the corresponding mortality is 8 to 13%, with an operative mortality of 4 to 6% [8] . Figure 3 depicts the remarkable increase in survival rates with CHD over the past 70 years. 
Repaired does not mean cured
Although originally assumed to be curative, it was realised over time that most interventions to treat CHD allowed these children to grow up without severe physical limitations, but with an -initially unexpected -increased longterm morbidity and mortality, manifesting once these patients were in the midst of their adult life [10] . Figure 4 shows some of the factors contributing to the cardiovascular burden observed in GUCH patients. Table 1 lists com- mon heart defects and the expected complications in adult life. The increased morbidity and mortality risk is reflected by a steadily growing number of re-hospitalisations within the adult CHD population, out of proportion to the pure increase in the population size over time [11] . Padrutt et al. recently presented numbers for GUCH patients followed up at the University Hospital Zurich: from 2005 to 2015, the number of adults under specialised care doubled, and the frequency of patients requiring hospital admission (e.g., for cardioversion) increased from 3.1 to 5.4% per year, a relative increase of 75% [12] . The main reasons for hospital admissions in adult CHD patients are supraventricular arrhythmias, lesion-specific surgery or percutaneous interventions, decompensated heart failure, ventricular tachycardias, the need for a pacemaker, an intracardiac defibrillator (ICD) or other elec- Prior to the repair procedure or intervention, the haemodynamic consequences of the defect and hypoxaemia in cases of cyanotic conditions pose an increased load to one or both ventricles. Peri-interventional damage and residual lesions or sequelae contribute to the cardiovascular burden after repair. Over time, aging and the emergence of acquired heart disease are an additional source of increasing cardiovascular morbidity. trophysiology procedures, pregnancy or delivery, evaluation and treatment for pulmonary hypertension, infective endocarditis and perioperative care for noncardiac surgery [13, 14] . In addition, within the aging CHD population, acquired morbidities (e.g., coronary artery disease, renal failure, diabetes, liver dysfunction, endocrinological and haematological disorders or cancer) are becoming important outcome factors in conjunction with the underlying congenital heart defect and add to the medical burden of these patients [15] . Some of today's adult patients also face complications related to limited diagnostic possibilities in the past. Screening blood products for the presence of hepatitis C virus became routine only in 1992. Adults with congenital heart surgery who received blood transfusions before 1992 have a 5-to 20-fold increased prevalence of hepatitis C infection [16] .
Specialised care saves lives
Based on experience and outcome data, specialised care by trained cardiologists of GUCH patients has been endorsed and recommended by different national and international societies within the last 20 years [4, 17, 18] . Minimal standards of care for GUCH patients in Switzerland are listed in table 2. Mylotte et al. observed a decline in GUCH mortality in a province-wide database of Québec, Canada after the publication of the first Canadian GUCH guidelines in 1997, which emphasised the importance of specialised care for adults with moderate or complex cardiac defects [19] . In a case-control analysis, referral to a specialised GUCH centre was associated with lower risk of death (odds ratio [OR] 0.82, 95% confidence interval [CI] 0.68-0.97), independent of comorbidities, age and gender. Survival improvement was highest for patients with complex defects. Several explanations are provided: the level of training and experience of the healthcare providers in GUCH centres, a 
Moderately complex defects
Atrioventricular septal defects (native or repaired) Arrhythmia, atrioventricular block, endocarditis, heart failure, pulmonary hypertension higher likelihood of use of practice guidelines and therefore less variability in care, the maximised use of medical advances, and the availability of congenital cardiac surgeons. There is growing evidence that substantially lower mortality rates (1.8 vs 4.8%) are achieved when a congenital heart surgery team is operating on GUCH patients, i.e., a cardiac surgeon who also operates on children, and not a "general" cardiac surgeon [20] . Currently, the University Hospitals of Lausanne/Geneva, Bern and Zurich provide the optimal surgical environment to operate on GUCH patients in Switzerland. Cardiac surgery in GUCH patients is characterised by a wide anatomical-clinical spectrum, frequent multiorgan involvement, and the absence of evidence-based data [21] . In contrast to cardiac surgery for acquired heart disease, there is no validated surgical risk score for GUCH patients [22] . All these factors enforce the need for meticulous preoperative planning and preparation of surgical interventions in GUCH patients, by a multidisciplinary team with experience in CHD.
Transition and patient education
CHD patients and their families need to be aware of the importance of uninterrupted specialised care. This requires education and a structured transition and transfer process in adolescence [23] . Studies on transfer destinations have shown that without a structured transition, up to 75% of adolescents with CHD are lost to follow-up once they reached adult life [24] . This has important implications: adults with CHD and a lapse of care are more likely to be symptomatic at the time they are readmitted to a hospital (OR 2.5, 95% CI 1-6), are more likely to have new haemodynamic problems or an additional cardiac diagnosis (OR 9.6, 95% CI 4-23), and have a 3-fold (95% CI 2-7) greater likelihood of requiring urgent cardiac interventions [25] . Multiple efforts are necessary to keep patients on board [26] . Protective and risk factors for care gaps in GUCH patients are presented in table 3. Organised transition programmes providing education on the heart defect, on healthy lifestyle, and coping and self-management strategies are emphasised, [27] . A transition coordinator is recommended to facilitate the transition process, and nurses are predestined for this position. Fifteen to 60 min educational sessions led by nurses have shown to increase patient's CHD knowledge [28, 29] .
Common cardiovascular problems in GUCH patients
The need for lifelong medical follow-up is related to the common cardiovascular complications seen in in GUCH patients.
Arrhythmias and stroke
More than half of all GUCH patients with complex CHD will develop arrhythmias by the age 65 years [30] . Arrhythmias are the most common cause of unscheduled hospital visits in adults with CHD and account for one third of all emergency admissions in this population [31] . All types of cardiac arrhythmias are prevalent, ranging from clinically occult arrhythmias, such as silent atrial fibrillation, to potentially fatal ventricular tachycardia. Table 4 illustrates the frequency of arrhythmia disturbances in different congenital defects. Residual anatomic or haemodynamic lesions and surgical scars from atrio-or ventriculotomies form the substrate for arrhythmias or dyssynchrony [32] . GUCH patients are routinely advised to consult their primary physician in the event of persistent palpitations or a sudden decrease in exercise capacity, in order to rule out arrhythmias with a routine 12-lead ECG or Holter ECG. A particular challenge in CHD patients with supraventricular arrhythmias is the decision when to start oral anticoagulation. Atrial fibrillation and intra-atrial re-entry tachycardia are the most common arrhythmias, and are associated with thrombosis and embolic events [33] . Among GUCH patients, the stroke incidence is 9 to 12 times higher than in the general population, particularly in younger adults (below age 55 years). Important predictors of ischaemic stroke, besides the absence of sinus rhythm, are the severity of the congenital defect, active infective endocarditis, the presence of endovenous pacemaker leads, heart failure, diabetes mellitus, and a recent history of myocardial infarction [33, 34] . The CHA 2 DS 2 -VASc score has proven benefits in identifying patients with nonvalvular atrial fibrillation at increased risk for stroke, but has a limited ability in GUCH patients [35] . Anticoagulation is recommended by experts in all GUCH patients with atrial fibrillation or intra-atrial re-entrant tachycardia and a history of previous intracardiac repair, cyanosis, after a Fontan palliation or in the presence of a systemic right ventricle, independent of the CHA 2 DS 2 VASc score [36] . Sudden cardiac death accounts for 15 to 25% of fatalities in GUCH patients [12, 37] . The incidence of sudden cardiac death is in the range of 1 per 1000 patient-years, and similar to the incidence of sustained ventricular tachycardia in these adults [38] . Intracardiac defibrillators (ICDs) are indicated in CHD adults for secondary prevention after resuscitation from sudden cardiac death and in those with spontaneous sustained ventricular tachycardia, after a careful workup has failed to identify a clear reversible cause. Selecting candidates for primary prevention is challenging.
In general, ICDs are recommended in patients with a systemic left ventricular ejection fraction ≤35%, biventricular physiology, and New York Heart Association (NYHA) class II or III symptoms [38] . They may also be considered in GUCH patients with a systemic right ventricular ejection fraction ≤35% and NYHA class III or IV, if additional risk factors are present, such as a history of syncope, or QRS duration >140 ms [39] .
Heart failure
Beside sudden cardiac death, heart failure is the other leading cause of death in GUCH patients. Together, they account for nearly half of all late mortality in mixed cohorts of children and adults [40, 41] . Mechanisms for heart failure in CHD are often lesion specific and may involve different pathophysiological pathways (table 5) . Recognition of heart failure symptoms can be delayed in GUCH patients because many have lived their entire life with the notion of a limited exercise capacity, do not perceive changes over time and underreport symptoms [42] . The Dutch CONCOR (CONgenital CORvitia Dutch national Registry) database reported an incidence of heart failure admission in GUCH patients of 1.2 per 1000 patient-years, which was 10 times higher than the incidence in the general population of adults of the same age [43] . GUCH patients admitted for heart failure had a 5-fold higher mortality than CHD patients without heart failure history, and the 1-and 3-year mortality after first heart failure admission were 24% and 35%, respectively. GUCH patients at high risk for heart failure are the ones with cardiac defects affecting the right ventricle, i.e. corrected tetralogy of Fallot, transposition of the great arteries with the right ventricle in systemic position, Ebstein's anomaly, or with a single ventricle physiology. Whereas medical heart failure treatment with beta-blockers, angiotensin converting-enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonists have proven benefits in left ventricular heart failure, the role of these agents has not been established in GUCH patients with right or single ventricular dysfunction [44] . Whereas neurohormonal modulation is the cornerstone of heart failure treatment in classic left heart failure patients and invasive haemodynamic assessment is reserved for patients with refractory heart failure, the reverse is true for most CHD diagnoses: careful haemodynamic assessment and structural interventions are the first step to consider in GUCH patients presenting with cardiac dysfunction [45] . Cardiac resynchronisation therapy has been used in a few CHD patients, but data from small studies in heterogeneous CHD populations could not clearly determine which GUCH patients will benefit, irrespective of anatomical difficulties for implantation [42] . Currently, the only established therapy for end-stage heart failure in CHD patients without pulmonary hypertension is heart transplantation [46] . Although early post-transplant mortality is increased in CHD patients, the 10-year survival is similar to non-CHD transplant recipients [47] . Ventricular assist devices can be used as a bridge to transplant [48] . Given the ubiquitous shortage of donor organs and the number of GUCH patients at risk, further medical options are currently being investigated in adults with a systemic right ventricle [49] .
Infective endocarditis CHD patients are at increased lifetime risk of infective endocarditis [50] . The risk varies with the underlying defect, but on average 1 in 1000 CHD patients suffers an episode of infective endocarditis per year [51] . This incidence is 20 to 30 times higher than the incidence observed in the general population (3-5 cases per 100 000 patients per year). In contemporary GUCH cohorts, the acute mortality of infective endocarditis is still 16%, and 1-year mortality is 19% [52] . Adults with repaired or palliated pulmonary atresia and adults with corrected congenital transposition of the great arteries have the highest incidence of infective endocarditis with 5.8 (95% CI 1.8-9.8) and 2.3 (95% CI 0.5-4.1) cases per 1000 patient-years, fol- [53] . Evidence supports a relationship between dental hygiene and the risk of developing endocarditis-associated bacteraemia after daily events such as tooth-brushing [54] . A large Swiss population study has shown that men are less likely to practice good dental hygiene than women [55] . It was shown that female gender and better disease knowledge are strongly related to good dental hygiene in GUCH patients [56] , reinforcing the concept that patients' education plays an important role in endocarditis prevention, as well as dental care. According to the current guidelines, optimal oral health is considered more important for infective endocarditis prevention than prophylactic antibiotics for dental procedures [57] . We discourage the empiric use of antibiotic treatments for suspected bacterial infections without evident focus, unless blood-cultures have been obtained prior to starting antibiotic therapy.
GUCH and pregnancy
Many women with CHD are in childbearing age and consider pregnancy [58] . From a cardiac point of view, pregnancy is a prolonged proarrhythmic and prothrombotic state with increased cardiac output and decreased peripheral resistance. The majority of women with CHD, normal biventricular function and no severe outflow tract obstruction tolerate pregnancy well. However, an impaired contractile function (e.g., a systemic right ventricle), a fixed obstruction (e.g., aortic coarctation, mitral stenosis, severe pulmonary hypertension), mechanical valves, aortic dilatation and residual cyanotic heart disease are conditions with an increased risk for maternal cardiovascular complications during pregnancy and delivery [59] . Extremely high risks of maternal mortality or morbidity are encountered in women with pulmonary arterial hypertension of any cause, severe systemic ventricular dysfunction with an ejection fraction <30% or in functional NYHA class III or IV, severe symptomatic mitral or aortic stenosis, native severe coarctation, Marfan syndrome with an ascending aortic diameter >45 mm or a bicuspid aortic valve with an ascending aortic diameter >50 mm, and in women with a history of peripartum cardiomyopathy and residual impairment of left ventricular function. If pregnancy occurs in these situations, termination should be discussed. A multidisciplinary team of cardiologists, obstetricians and anaesthesiologists should monitor CHD patients before and during pregnancy, delivery and the postpartum period. After delivery, cardiac output may take up to 6 months to return to prepregnancy levels. Individual preconception counselling of women with CHD concerning contraception, pregnancy risks and inheritance is prerequisite to an informed decision.
End-of-life discussions and advanced care planning
Death is not predictable in most CHD patients, and heart failure symptoms may manifest late in the disease trajectory, making early end-of-life discussions indispensable. This includes the completion of advanced directives, palliative care and resuscitation options, and identifying an attorney [60] . As in many other disciplines, advanced care planning (ACP) discussions are rarely held with GUCH patients. In a Canadian GUCH centre, out of 200 patients only 2 (1%) recalled having discussed ACP, whereas 24 of 48 (50%) healthcare providers indicated that they discussed life expectancy, ACP and resuscitation preferences regularly with their patients [61] . Patients' preferences for ACP did not depend on the CHD complexity, but healthcare providers stated that they discussed ACP more often with patients with complex lesions. Similar results were found in a recent survey of an American GUCH centre [62] . Patients favour ACP discussions prior to a life-threatening illness, but the physicians' focus on life, rather on death, hindered a timely initiation [63] . Adult CHD poses many challenges, not only to patients, but also to their treating physicians.
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